Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

RSV competition
Shionogi's L inhibitor challenge study expected to be completed by Q3 - exactly the same as ENTA
I view this as the stiffest competition to ENTA's RSV programs

https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2024/e20240614.pdf

Keller : Indeed, Enanta’s compound is the closest competitor in terms of mechanism. As you understand, we
are also conducting challenge trials to collect clinical data. What we are confident about is that this targeting
mechanism allows us to rapidly reduce viral load and achieve efficacy.
We think that data will be available by the end of this year.

Muraoka : As for your compound S-337395, when will we see the clinical data on it?
Keller : The results of the challenge study are important data. They will come out later this fiscal year.
Muraoka : Is it the second or the third?
Keller : I think it will be in Q3.